Results 21 to 30 of about 1,130 (117)

Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report

Brain, Behavior, & Immunity - Health, 2023
Gastrointestinal stromal tumors (GISTs) are tumors of the digestive tract. To date, there have been no neurological paraneoplastic syndromes or symptoms associated with metastatic GISTs.
Claire Drom, Kayla Schenheit, Morgan Matzke, Ahmed Zayed Obeidat, Jessica Molinaro, John Charlson, Jennifer M. Knight   +6 more
doaj   +1 more source

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

BMC Cancer, 2021
Background Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST).
Margaret von Mehren, Michael C. Heinrich, Hongliang Shi, Sergio Iannazzo, Raymond Mankoski, Saša Dimitrijević, Gerard Hoehn, Silvia Chiroli, Suzanne George   +8 more
doaj   +1 more source

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia

Leukemia Research Reports, 2023
Background: Atypical chronic myeloid leukemia (aCML) is a rare myelodysplastic/myeloproliferative neoplasm. There is no proven standard of care treatment and the only curative option available is hematopoietic stem cell transplant.
Lyndsey Sandow, Michael Heinrich
doaj   +1 more source

Effective targeting of PDGFRA-altered high-grade glioma with avapritinib [PDF]

Cancer Cell
Jakub Neradil, Mariella Filbin, Natalie Jaeger   +2 more
exaly   +2 more sources

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis

Therapeutic Advances in Hematology, 2023
In systemic mastocytosis, cytoreductive treatment is indicated for advanced systemic mastocytosis (AdvSM) variants. The treatment scenario is rapidly diversifying especially with the introduction of KIT tyrosine kinase inhibitors. Avapritinib is a second-
Francesco Mannelli, Francesca Crupi, Roberta Zanotti, Livio Pagano, Davide Rapezzi, Ilaria Tanasi, Marianna Criscuolo, Massimiliano Bonifacio, Alberto Fresa, Paola Guglielmelli, Alessandro M. Vannucchi   +10 more
doaj   +1 more source

Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis

Diagnostics, 2023
Advanced systemic mastocytosis (AdvSM) is a rare haematological neoplasm characterised by the accumulation of neoplastic mast cells (MCs) in various organs, resulting in organ dysfunction and reduced life expectancy.
Scott Veitch, Deepti H. Radia
doaj   +1 more source

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors

Frontiers in Oncology, 2022
Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have a different pathogenesis, clinical characteristics, and treatment response ...
Yingchao Sun, Lei Yue, Pengfu Xu, Weiling Hu, Weiling Hu, Weiling Hu   +5 more
doaj   +1 more source

The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies

Molecules, 2023
The altered activation or overexpression of protein kinases (PKs) is a major subject of research in oncology and their inhibition using small molecules, protein kinases inhibitors (PKI) is the best available option for the cure of cancer.
George Mihai Nitulescu, Gheorghe Stancov, Oana Cristina Seremet, Georgiana Nitulescu, Dragos Paul Mihai, Cosmina Gabriela Duta-Bratu, Stefania Felicia Barbuceanu, Octavian Tudorel Olaru   +7 more
doaj   +1 more source

Advances in the management of gastrointestinal stromal tumors (GISTs)

Nowotwory, 2020
Gastrointestinal stromal tumors are rare neoplasms developing from cells of Cajal in the gastrointestinal tract. The mainstay of such tumors treatment is surgery, whenever possible. The therapeutic management of inoperable and metastatic disease is based
Monika Dudzisz-Śledź, Piotr Rutkowski
doaj   +1 more source

Target Therapies for Systemic Mastocytosis: An Update

Pharmaceuticals, 2022
Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MCs) in extra-cutaneous organs. It could be divided into indolent SM, smoldering SM, SM with an associated hematologic (non-MC lineage) neoplasm, aggressive SM, and ...
Mariarita Sciumè, Claudio De Magistris, Nicole Galli, Eleonora Ferretti, Giulia Milesi, Pasquale De Roberto, Sonia Fabris, Federica Irene Grifoni   +7 more
doaj   +1 more source